Neuronetics is trading at $2.17, down 10.49%, with no company-specific negative announcement surfaced to explain the decline. - On November 6, healthcare stocks fell 1.48% amid post-election policy concerns, adding possible sector pressure but not fully explaining the drop. - November 4 results showed revenue growth and improved profitability; full-year revenue guidance was unchanged. - B. Riley maintained Buy and raised its November 6 price target to $6, a positive action.